ArticleNature2022
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 399 papers.
0numbers the graph read from it
0cells of the map it votes in
399citing papers in PubMed
37.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
399 citing papers in PubMed, 668 citations in OpenAlex.
- Syncytium-forming HSV-1 in cancer gene therapy: From molecular mechanisms to clinical translation.Virulence · 2026Review
- SARS-CoV-2 Delta variant-specific ORF3a mutations destabilize lysosomal homeostasis to trigger lysosomal damage-mediated cell death.Communications biology · 2026Article
- GC content mismatch of transgene destabilizes RNA virus genomes.Journal of virology · 2026Article
- Peptides containing SARS-CoV-2 spike-protein residues are antagonists of α7 and α9α10 nAChRs and modulate interleukin-1β release from human monocytic THP-1 cells.The Journal of biological chemistry · 2026Article
- Immune evasion, infectivity, and membrane fusion of SARS-CoV-2 variants LP.8.1.1, XEC.25.1, XFG, and NB.1.8.1.Microbiology spectrum · 2026Article
- ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2.Molecular biomedicine · 2026Article
- Nanobodies targeting SARS-CoV-2 variants.Acta pharmaceutica Sinica. B · 2026Review
- Viral syncytia evolve to resist interferon.Nature communications · 2026Article
- Emerging Novel SARS-CoV-2 Subvariants and the Advantages of AI-ML in Deciphering the Mutation Trends, Genomic Surveillance and Vaccine Development.Health science reports · 2026Article
- Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.Journal of virology · 2026Article
- Programmable antibody-based chimeric entry receptors for sarbecoviruses.Communications biology · 2026Article
- From Bench to Insight: Rapid Pathogen Genomic Surveillance Workflow for SARS-CoV-2 and Emerging Pathogens.Genes · 2026Article
- D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026Article
- Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication.The Journal of general virology · 2026Article
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
- Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2.Viruses · 2026Review
- TNF inhibits SARS-CoV-2 induced cell-cell fusion through activating the SDC4-RhoA signaling to promote actin bundles formation.Cell insight · 2026Article
- Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial.NPJ vaccines · 2026Article
- Pathological characteristics of SARS-CoV-2 variants and immune responses induced in a COVID-19 macaque model.Communications biology · 2026Article
339 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 13 institutions in 3 countries.
Akatsuki Saito *Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.ORCID http://orcid.org/0000-0002-2792-4399
Takashi Irie *Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0003-3765-8482
Rigel Suzuki *Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
Tadashi Maemura *Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Hesham Nasser *Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.ORCID http://orcid.org/0000-0001-9163-1665
Keiya Uriu *Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yusuke Kosugi *Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kotaro ShirakawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-7469-1276
Kenji SadamasuTokyo Metropolitan Institute of Public Health, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0541-706X
Izumi KimuraDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Jumpei ItoDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0440-8321
Jiaqi WuDepartment of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8266-020X
Mutsumi ItoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Seiya YamayoshiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7768-5157
Samantha LoeberDepartment of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.
Masumi TsudaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.ORCID http://orcid.org/0000-0001-5400-5905
Lei WangDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.ORCID http://orcid.org/0000-0001-6145-395X
Seiya OzonoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1764-2937
Erika P ButlertanakaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.ORCID http://orcid.org/0000-0002-7633-7238
Yuri L TanakaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.ORCID http://orcid.org/0000-0001-9866-4398
Ryo ShimizuDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Kenta ShimizuDepartment of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.ORCID http://orcid.org/0000-0002-3825-7018
Kumiko YoshimatsuInstitute for Genetic Medicine, Hokkaido University, Hokkaido, Japan.ORCID http://orcid.org/0000-0002-0062-2753
Ryoko KawabataInstitute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takemasa SakaguchiInstitute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-3754-1252
Kenzo TokunagaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2625-5322
Isao YoshidaTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Hiroyuki AsakuraTokyo Metropolitan Institute of Public Health, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2572-6786
Mami NagashimaTokyo Metropolitan Institute of Public Health, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8069-9250
Yasuhiro KazumaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-1046-8286
Ryosuke NomuraDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshihito HorisawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazuhisa YoshimuraTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-7678-4284
Masaki ImaiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Genotype to Phenotype Japan (G2P-Japan) Consortium
Shinya TanakaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan. tanaka@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0001-6470-3301
So NakagawaDepartment of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan. so@tokai.ac.jp.ORCID http://orcid.org/0000-0003-1760-3839
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. ikedat@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0003-2869-9450
Takasuke FukuharaDepartment of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan. fukut@pop.med.hokudai.ac.jp.ORCID http://orcid.org/0000-0001-5471-8331
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. yoshihiro.kawaoka@wisc.edu.ORCID http://orcid.org/0000-0001-5061-8296
Kei SatoDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. KeiSato@g.ecc.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0003-4431-1380
National Institute of Infectious Diseases · JPHokkaido University · JPKumamoto University · JPKyoto University · JPTokyo Metropolitan Institute of Public Health · JPTokyo University of Science · JPUniversity of Miyazaki · JPHiroshima University · JPTokai University · JPUniversity of Wisconsin–Madison · USHealth Sciences University of Hokkaido · JPHokusho University · JPSuez Canal University · EG
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the current coronavirus disease 2019 (COVID-19) pandemic, a variety of mutations have accumulated in the viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, at the time of writing, four variants of concern are considered to be potentially hazardous to human society
Indexed as
Membrane FusionMutationAmino Acid SubstitutionAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19CricetinaeGiant CellsMaleMesocricetusPhylogenySARS-CoV-2Spike Glycoprotein, CoronavirusVirulenceVirus ReplicationAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.